Πέμπτη 24 Ιανουαρίου 2019

ClinicalTrials

Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC
Conditions:   Metastatic Head and Neck Squamous Cell Carcinoma;   Recurrent Head and Neck Squamous Cell CarcinomaIntervention:   Drug: PembrolizumabSponsors:   University College, London;   Merck Sharp & Dohme Corp.Not yet recruiting
ClinicalTrials
1d
Bevacizumab and Pembrolizumab Combination in EBER-ISH Positive NPC
Conditions:   Locally Recurrent Cancer;   Metastatic Nasopharyngeal CancerInterventions:   Drug: pembrolizumab;   Drug: bevacizumabSponsors:   National University Hospital, Singapore;   Merck Sharp & Dohme Corp.Not yet recruiting
ClinicalTrials
1d
the Dissection of Lymph Node Posterior to Right Recurrent Laryngeal Nerve for Papillary Thyroid Carcinoma
Condition:   Lymph Node MetastasesIntervention:   Procedure: lymph node dissectionSponsor:   Zhejiang UniversityNot yet recruiting
ClinicalTrials
1d
Central Cervical Dissection for Clinical Node Negative Papillary Thyroid Carcinoma
Condition:   Lymph Node MetastasesIntervention:   Procedure: lymph node dissectionSponsor:   Zhejiang UniversityNot yet recruiting
ClinicalTrials
1d
N-Force Screws Augmented With N-Force Blue in Hip Fractures
Conditions:   Intracapsular Proximal Femur Fracture;   Garden Grade I Subcapital Fracture of Femoral Neck;   Garden Grade II Subcapital Fracture of Femoral NeckIntervention:   Device: N-Force Screws Augmented with N-Force BlueSponsor:   Zimmer BiometNot yet recruiting
ClinicalTrials
1d

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου